Chemogenomic Profiling of a Plasmodium falciparum Transposon Mutant Library Reveals Shared Effects of Dihydroartemisinin and Bortezomib on Lipid Metabolism and Exported Proteins

Malaria control is seriously threatened by the emergence and spread of Plasmodium falciparum resistance to the leading antimalarial, artemisinin. The potent killing activity of artemisinin results from oxidative damage unleashed by free heme activation released by hemoglobin digestion. ABSTRACT The antimalarial activity of the frontline drug artemisinin involves generation of reactive oxygen species (ROS) leading to oxidative damage of parasite proteins. To achieve homeostasis and maintain protein quality control in the overwhelmed parasite, the ubiquitin-proteasome system kicks in. Even though molecular markers for artemisinin resistance like pfkelch13 have been identified, the intricate network of mechanisms driving resistance remains to be elucidated. Here, we report a forward genetic screening strategy that enables a broader identification of genetic factors responsible for altering sensitivity to dihydroartemisinin (DHA) and a proteasome inhibitor, bortezomib (BTZ). Using a library of isogenic piggyBac mutants in P. falciparum, we defined phenotype-genotype associations influencing drug responses and highlighted shared mechanisms between the two processes, which mainly included proteasome-mediated degradation and the lipid metabolism genes. Additional transcriptomic analysis of a DHA/BTZ-sensitive piggyBac mutant showed it is possible to find differences between the two response mechanisms on the specific components for regulation of the exportome. Our results provide further insight into the molecular mechanisms of antimalarial drug resistance. IMPORTANCE Malaria control is seriously threatened by the emergence and spread of Plasmodium falciparum resistance to the leading antimalarial, artemisinin. The potent killing activity of artemisinin results from oxidative damage unleashed by free heme activation released by hemoglobin digestion. Although the ubiquitin-proteasome system is considered critical for parasite survival of this toxicity, the diverse genetic changes linked to artemisinin resistance are complex and, so far, have not included the ubiquitin-proteasome system. In this study, we use a systematic forward genetic approach by screening a library of P. falciparum random piggyBac mutants to decipher the genetic factors driving malaria parasite responses to the oxidative stress caused by antimalarial drugs. This study compares phenotype-genotype associations influencing dihydroartemisinin responses with the proteasome inhibitor bortezomib to delineate the role of ubiquitin-proteasome system. Our study highlights shared and unique pathways from the complex array of molecular processes critical for P. falciparum survival resulting from the oxidative damage of artemisinin.

[1]  Zbynek Bozdech,et al.  Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response , 2022, Communications Biology.

[2]  Cyrille Y. Botté,et al.  The flexibility of Apicomplexa parasites in lipid metabolism , 2022, PLoS pathogens.

[3]  T. Horii,et al.  Evidence of Artemisinin-Resistant Malaria in Africa. , 2021, The New England journal of medicine.

[4]  Joana C. Silva,et al.  Integration of population and functional genomics to understand mechanisms of artemisinin resistance in Plasmodium falciparum , 2021, International journal for parasitology. Drugs and drug resistance.

[5]  P. Gilson,et al.  Defining the Essential Exportome of the Malaria Parasite. , 2021, Trends in parasitology.

[6]  Zbynek Bozdech,et al.  Artemisinin-resistant K13 mutations rewire Plasmodium falciparum’s intra-erythrocytic metabolic program to enhance survival , 2021, Nature Communications.

[7]  J. Rayner,et al.  The apicoplast link to fever-survival and artemisinin-resistance in the malaria parasite , 2020, Nature Communications.

[8]  H. Kato,et al.  A prospective mechanism and source of cholesterol uptake by Plasmodium falciparum-infected erythrocytes co-cultured with HepG2 cells. , 2020, Parasitology international.

[9]  Caroline L. Ng,et al.  P. falciparum artemisinin resistance: the effect of heme, protein damage, and parasite cell stress response. , 2020, ACS infectious diseases.

[10]  E. Hayakawa,et al.  Real-time cholesterol sorting in Plasmodium falciparum-erythrocytes as revealed by 3D label-free imaging , 2020, Scientific Reports.

[11]  B. Bergmann,et al.  A Kelch13-defined endocytosis pathway mediates artemisinin resistance in malaria parasites , 2020, Science.

[12]  S. Ralph,et al.  Decreased K13 Abundance Reduces Hemoglobin Catabolism and Proteotoxic Stress, Underpinning Artemisinin Resistance. , 2019, Cell reports.

[13]  J. Rayner,et al.  Genome-Scale Identification of Essential Metabolic Processes for Targeting the Plasmodium Liver Stage , 2019, Cell.

[14]  Gennady Korotkevich,et al.  Fast gene set enrichment analysis , 2019, bioRxiv.

[15]  Remo S. Schmidt,et al.  Stochastic protein alkylation by antimalarial peroxides. , 2019, ACS infectious diseases.

[16]  A. Stewart,et al.  A CRISPR platform for targeted in vivo screens identifies Toxoplasma gondii virulence factors in mice , 2019, Nature Communications.

[17]  Steven L Salzberg,et al.  Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype , 2019, Nature Biotechnology.

[18]  M. Oyama,et al.  A High-Resolution Map of SBP1 Interactomes in Plasmodium falciparum-infected Erythrocytes , 2019, iScience.

[19]  D. Kwiatkowski,et al.  The origins of malaria artemisinin resistance defined by a genetic and transcriptomic background , 2018, Nature Communications.

[20]  M. Ferdig,et al.  Altered expression of K13 disrupts DNA replication and repair in Plasmodium falciparum , 2018, BMC Genomics.

[21]  P. Gilson,et al.  Knockdown of the translocon protein EXP2 in Plasmodium falciparum reduces growth and protein export , 2018, PloS one.

[22]  D. Hartl,et al.  Mutations in Plasmodium falciparum actin-binding protein coronin confer reduced artemisinin susceptibility , 2018, Proceedings of the National Academy of Sciences.

[23]  P. Preiser,et al.  tRNA epitranscriptomics and biased codon are linked to proteome expression in Plasmodium falciparum , 2018, Molecular systems biology.

[24]  S. Ralph,et al.  Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome , 2018, Nature Communications.

[25]  R. Sauer,et al.  A mutagenesis screen for essential plastid biogenesis genes in human malaria parasites , 2018, bioRxiv.

[26]  D. Goldberg,et al.  EXP 2 is a nutrient-permeable channel in the vacuolar membrane of Plasmodium and is essential for protein export via , 2018 .

[27]  M. Foley,et al.  Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance , 2018, Proceedings of the National Academy of Sciences.

[28]  J. Rayner,et al.  Uncovering the essential genes of the human malaria parasite Plasmodium falciparum by saturation mutagenesis , 2018, Science.

[29]  K. Williamson,et al.  The proteasome as a target to combat malaria: hits and misses. , 2018, Translational research : the journal of laboratory and clinical medicine.

[30]  P. Rosenthal,et al.  Plasmodium falciparum Falcipain-2a Polymorphisms in Southeast Asia and Their Association With Artemisinin Resistance , 2018, The Journal of infectious diseases.

[31]  Zbynek Bozdech,et al.  Oxidative stress and protein damage responses mediate artemisinin resistance in malaria parasites , 2018, PLoS pathogens.

[32]  Ana Rodriguez,et al.  Inhibiting the Plasmodium eIF2α Kinase PK4 Prevents Artemisinin-Induced Latency. , 2017, Cell host & microbe.

[33]  V. Muralidharan,et al.  The Exported Chaperone PfHsp70x Is Dispensable for the Plasmodium falciparum Intraerythrocytic Life Cycle , 2017, mSphere.

[34]  M. Bogyo,et al.  Protein Degradation Systems as Antimalarial Therapeutic Targets. , 2017, Trends in parasitology.

[35]  J. Rayner,et al.  Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes , 2017, Cell.

[36]  D. Ménard,et al.  Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia. , 2016, The American journal of tropical medicine and hygiene.

[37]  D. Saunders,et al.  Ex vivo piperaquine resistance developed rapidly in Plasmodium falciparum isolates in northern Cambodia compared to Thailand , 2016, Malaria Journal.

[38]  M. Blackman,et al.  Regulation and Essentiality of the StAR-related Lipid Transfer (START) Domain-containing Phospholipid Transfer Protein PFA0210c in Malaria Parasites* , 2016, The Journal of Biological Chemistry.

[39]  Manuel Llinás,et al.  Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond , 2016, PLoS pathogens.

[40]  J. Rayner,et al.  Quantitative insertion-site sequencing (QIseq) for high throughput phenotyping of transposon mutants , 2016, Genome research.

[41]  Zbynek Bozdech,et al.  DNA damage regulation and its role in drug-related phenotypes in the malaria parasites , 2016, Scientific Reports.

[42]  J. Hemingway,et al.  Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7 , 2016, Proceedings of the National Academy of Sciences.

[43]  L. Tilley,et al.  Haemoglobin degradation underpins the sensitivity of early ring stage Plasmodium falciparum to artemisinins , 2016, Journal of Cell Science.

[44]  Bin Liu,et al.  Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum , 2015, Nature Communications.

[45]  Geoffrey H. Siwo,et al.  Chemogenomic profiling of Plasmodium falciparum as a tool to aid antimalarial drug discovery , 2015, Scientific Reports.

[46]  Zbynek Bozdech,et al.  TARGETING THE CELL STRESS RESPONSE OF PLASMODIUM FALCIPARUM TO OVERCOME ARTEMISININ RESISTANCE , 2015 .

[47]  Scott Emrich,et al.  A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria , 2015, Nature.

[48]  Frank Schwach,et al.  A Genome-Scale Vector Resource Enables High-Throughput Reverse Genetic Screening in a Malaria Parasite , 2015, Cell host & microbe.

[49]  John C. Tan,et al.  Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. , 2015, The Journal of infectious diseases.

[50]  R. Hallett,et al.  The Mu Subunit of Plasmodium falciparum Clathrin-Associated Adaptor Protein 2 Modulates In Vitro Parasite Response to Artemisinin and Quinine , 2015, Antimicrobial Agents and Chemotherapy.

[51]  D. Kwiatkowski,et al.  Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance , 2015, Science.

[52]  Gilean McVean,et al.  Genetic architecture of artemisinin-resistant Plasmodium falciparum , 2015, Nature Genetics.

[53]  L. Imlay,et al.  Isoprenoid Metabolism in Apicomplexan Parasites , 2014, Current Clinical Microbiology Reports.

[54]  E. Ashley,et al.  Artemisinin resistance – modelling the potential human and economic costs , 2014, Malaria Journal.

[55]  Anusha M. Gopalakrishnan,et al.  Antimalarial Action of Artesunate Involves DNA Damage Mediated by Reactive Oxygen Species , 2014, Antimicrobial Agents and Chemotherapy.

[56]  D. Goldberg,et al.  PTEX component HSP101 mediates export of diverse malaria effectors into host erythrocytes , 2014, Nature.

[57]  T. Clark,et al.  Directional Selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu Loci of Plasmodium falciparum in Kenyan Children Treated With ACT , 2014, The Journal of infectious diseases.

[58]  M. Gatton,et al.  Fatty Acid Synthesis and Pyruvate Metabolism Pathways Remain Active in Dihydroartemisinin-Induced Dormant Ring Stages of Plasmodium falciparum , 2014, Antimicrobial Agents and Chemotherapy.

[59]  Zhijian J. Chen,et al.  K33-Linked Polyubiquitination of Coronin 7 by Cul3-KLHL20 Ubiquitin E3 Ligase Regulates Protein Trafficking. , 2014, Molecular cell.

[60]  L. Kats,et al.  An exported kinase (FIKK4.2) that mediates virulence-associated changes in Plasmodium falciparum-infected red blood cells. , 2014, International journal for parasitology.

[61]  G. Biagini,et al.  The proliferating cell hypothesis: a metabolic framework for Plasmodium growth and development☆ , 2014, Trends in parasitology.

[62]  B. Genton,et al.  A molecular marker of artemisinin-resistant Plasmodium falciparum malaria , 2013, Nature.

[63]  C. Sibley Tracking artemisinin resistance in Plasmodium falciparum. , 2013, The Lancet. Infectious diseases.

[64]  B. Striepen,et al.  Lipid synthesis in protozoan parasites: a comparison between kinetoplastids and apicomplexans. , 2013, Progress in lipid research.

[65]  K. Haldar,et al.  Identification of a Plasmodium falciparum Phospholipid Transfer Protein* , 2013, The Journal of Biological Chemistry.

[66]  T. Gilberger,et al.  Identification of New PNEPs Indicates a Substantial Non-PEXEL Exportome and Underpins Common Features in Plasmodium falciparum Protein Export , 2013, PLoS pathogens.

[67]  N. Azas,et al.  A decade of Plasmodium falciparum metabolic pathways of therapeutic interest to develop new selective antimalarial drugs. , 2013, Mini reviews in medicinal chemistry.

[68]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[69]  A. Cowman,et al.  Role of Plasmepsin V in Export of Diverse Protein Families from the Plasmodium falciparum Exportome , 2013, Traffic.

[70]  C. Karema,et al.  Artemisinin resistance in rodent malaria - mutation in the AP2 adaptor μ-chain suggests involvement of endocytosis and membrane protein trafficking , 2013, Malaria Journal.

[71]  C. Karema,et al.  Artemisinin resistance in rodent malaria - mutation in the AP2 adaptor μ-chain suggests involvement of endocytosis and membrane protein trafficking , 2013, Malaria Journal.

[72]  T. Egan,et al.  Insights into the role of heme in the mechanism of action of antimalarials. , 2013, ACS chemical biology.

[73]  P. Gilson,et al.  Plasmodium falciparum‐encoded exported hsp70/hsp40 chaperone/co‐chaperone complexes within the host erythrocyte , 2012, Cellular microbiology.

[74]  Leann Tilley,et al.  Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion , 2011, Proceedings of the National Academy of Sciences.

[75]  J. Derisi,et al.  RNA-Seq analysis of splicing in Plasmodium falciparum uncovers new splice junctions, alternative splicing and splicing of antisense transcripts , 2011, Nucleic acids research.

[76]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[77]  Ravikant Ranjan,et al.  PfPI3K, a phosphatidylinositol-3 kinase from Plasmodium falciparum, is exported to the host erythrocyte and is involved in hemoglobin trafficking. , 2010, Blood.

[78]  Aaron R. Quinlan,et al.  BEDTools: a flexible suite of utilities for comparing genomic features , 2010, Bioinform..

[79]  E. Ashley,et al.  Varying efficacy of artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies , 2009, Malaria Journal.

[80]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[81]  K. Haldar,et al.  The Malaria Secretome: From Algorithms to Essential Function in Blood Stage Infection , 2008, PLoS pathogens.

[82]  J. Lelièvre,et al.  Trioxaquines and Heme-Artemisinin Adducts Inhibit the In Vitro Formation of Hemozoin Better than Chloroquine , 2007, Antimicrobial Agents and Chemotherapy.

[83]  P. T. Englund,et al.  A fatty-acid synthesis mechanism specialized for parasitism , 2007, Nature Reviews Microbiology.

[84]  R. Shoemaker The NCI60 human tumour cell line anticancer drug screen , 2006, Nature Reviews Cancer.

[85]  C. Tomasetto,et al.  Give lipids a START: the StAR-related lipid transfer (START) domain in mammals , 2005, Journal of Cell Science.

[86]  Melanie Rug,et al.  Targeting Malaria Virulence and Remodeling Proteins to the Host Erythrocyte , 2004, Science.

[87]  Travis Harrison,et al.  A Host-Targeting Signal in Virulence Proteins Reveals a Secretome in Malarial Infection , 2004, Science.

[88]  Fuencisla Matesanz,et al.  The C-terminal domain of the Plasmodium falciparum acyl-CoA synthetases PfACS1 and PfACS3 functions as ligand for ankyrin. , 2003, Molecular and biochemical parasitology.

[89]  J. Breslow,et al.  StAR-related Lipid Transfer (START) Proteins: Mediators of Intracellular Lipid Metabolism* , 2003, Journal of Biological Chemistry.

[90]  S. Ralph,et al.  A Type II Pathway for Fatty Acid Biosynthesis Presents Drug Targets in Plasmodium falciparum , 2003, Antimicrobial Agents and Chemotherapy.

[91]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[92]  J. Hurley,et al.  Structure and lipid transport mechanism of a StAR-related domain , 2000, Nature Structural Biology.

[93]  T. K. Dien,et al.  Clinical Pharmacology and Therapeutic Potential of Artemisinin and its Derivatives in the Treatment of Malaria , 1996, Drugs.

[94]  H. Vial,et al.  Correlation of the efficiency of fatty acid derivatives in suppressing Plasmodium falciparum growth in culture with their inhibitory effect on acyl-CoA synthetase activity. , 1988, Molecular and biochemical parasitology.

[95]  H. Vial,et al.  Acyl-CoA synthetase activity in Plasmodium knowlesi-infected erythrocytes displays peculiar substrate specificities. , 1988, Biochimica et biophysica acta.

[96]  G. McFadden,et al.  Fatty acid metabolism in the Plasmodium apicoplast: Drugs, doubts and knockouts. , 2015, Molecular and biochemical parasitology.

[97]  C. Tomasetto,et al.  START ships lipids across interorganelle space. , 2014, Biochimie.

[98]  A. Alcina,et al.  The Plasmodium falciparum fatty acyl-CoA synthetase family (PfACS) and differential stage-specific expression in infected erythrocytes. , 2003, Molecular and biochemical parasitology.